IRWD Ironwood Pharmaceuticals, Inc.
QT87| Index | — | P/E | 4.55 | EPS (ttm) | 0.77 | Insider Own | 15.65% | Shs Outstand | 165.24M | Perf Week | 1.16% |
| Market Cap | 578.34M | Forward P/E | 2.66 | EPS next Y | 1.32 | Insider Trans | -0.58% | Shs Float | 159.10M | Perf Month | -6.91% |
| Enterprise Value | 893.34M | PEG | — | EPS next Q | 0.32 | Short Float | 9.99% | Perf Quarter | -20.81% | ||
| Income | 130.00M | P/S | 1.48 | EPS this Y | 948.54% | Short Ratio | 8.00 | Perf Half Y | -21.17% | ||
| Sales | 390.00M | P/B | — | EPS next Y | 7.63% | ROA | 45.55% | Short Interest | 15.89M | Perf YTD | 3.86% |
| Book/sh | -0.98 | P/C | 7.32 | EPS next 5Y | -28.48% | ROE | — | 52W High | 5.78 -39.45% | Perf Year | 131.79% |
| Cash/sh | 0.48 | P/FCF | 3.11 | EPS past 3/5Y | -46.14% -25.65% | ROIC | 57.85% | 52W Low | 1.47 138.10% | Perf 3Y | -60.94% |
| Dividend Est. | — | EV/EBITDA | 3.69 | Sales past 3/5Y | -10.36% -5.37% | Gross Margin | 99.76% | Volatility | 3.77% 4.63% | Perf 5Y | -73.14% |
| Dividend TTM | — | EV/Sales | 2.29 | EPS Y/Y TTM | — | Oper. Margin | 60.64% | ATR (14) | 0.17 | Perf 10Y | -74.84% |
| Dividend Ex-Date | — | Quick Ratio | 6.06 | Sales Y/Y TTM | 26.21% | Profit Margin | 33.36% | RSI (14) | 40.51 | Recom | 2.73 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.06 | EPS Q/Q | 121.43% | SMA20 | -3.38% | Beta | 0.25 | Target Price | 6.68 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 32.94% | SMA50 | -11.55% | Rel Volume | 0.76 | Prev Close | 3.62 |
| Employees | 100 | LT Debt/Eq | — | Earnings | Feb 18 | SMA200 | -12.18% | Avg Volume | 1.94M | Price | 3.50 |
| IPO Date | Feb 03, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -3.12% -1.57% | Net Debt/EBITDA | 1.30 | Volume | 1,467,616 | Change | -3.31% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-26-26 | Reiterated | Jefferies | Hold | $3.70 |
| Jan-05-26 | Reiterated | Craig-Hallum | Buy | $3.80 → $5.70 |
| Jan-05-26 | Upgrade | Citizens | Market Perform → Market Outperform | |
| Nov-26-25 | Reiterated | Craig-Hallum | Buy | $1.70 → $3.80 |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight | |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold | |
| Apr-14-25 | Reiterated | Leerink Partners | Market Perform | $5.00 → $1.00 |
| Jan-31-25 | Reiterated | Wells Fargo | Overweight | $12 → $7.00 |
| Sep-09-24 | Initiated | Leerink | Market Perform | $5.00 |
| Aug-09-24 | Reiterated | Wells Fargo | Overweight | $14 → $12 |
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 390 | 296 | 351 | 443 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 8 | 6 | — | — | — | — | — | |
| Gross Profit | 389 | 296 | 344 | 437 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 64 | 82 | 0 | 0 | — | — | — | — | — | |
| Research and Development | 87 | 95 | 111 | 116 | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | 140 | 1,266 | — | — | — | — | — | |
| Operating Income | 237 | 119 | 93 | -945 | — | — | — | — | — | |
| Interest Expense | 32 | 33 | 33 | 22 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | -16 | 5 | 19 | — | — | — | — | — | |
| Net Income Before Taxes | 207 | 70 | 65 | -948 | — | — | — | — | — | |
| Income Taxes | 77 | 46 | 64 | 83 | — | — | — | — | — | |
| Consolidated Net Income | 130 | 24 | 1 | -1,002 | — | — | — | — | — | |
| Net Income From Continuing Operations | 130 | 24 | 1 | -1,032 | — | — | — | — | — | |
| Net Income | 130 | 24 | 1 | -1,002 | — | — | — | — | — | |
| EPS (Recurring) | 0.80 | 0.15 | 0.01 | -6.45 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.80 | 0.15 | 0.01 | -6.45 | — | — | — | — | — | |
| EPS (Diluted) | 0.77 | 0.15 | 0.01 | -6.45 | — | — | — | — | — | |
| EBITDA | 242 | 105 | 98 | 197 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 4.55 | 22.47 | 805.45 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.48 | 1.84 | 2.01 | 4.00 | — | — | — | — | — | |
| Gross Margin | 99.74 | 100.00 | 98.01 | 98.65 | — | — | — | — | — | |
| Operating Margin | 60.77 | 40.20 | 26.50 | -213.32 | — | — | — | — | — | |
| Net Margin | 33.33 | 8.11 | 0.28 | -226.19 | — | — | — | — | — | |
| Shares Outstanding | 165 | 162 | 159 | 155 | — | — | — | — | — | |
| Market Capitalization | 578 | 546 | 704 | 1,773 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Silver Ronald | PFO & PAO | Jul 07 '26 | Sale | 4.52 | 127,890 | 578,063 | 313,680 | Jul 09 |
| McHugh Julie | Director | Jun 16 '26 | Sale | 3.73 | 21,571 | 80,460 | 250,749 | Jun 17 |
| DENNER ALEXANDER J | Director | Mar 17 '26 | Sale | 3.05 | 6,730,800 | 20,530,448 | 9,188,635 | Mar 17 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | Feb 24 '26 | Sale | 3.66 | 17,012 | 62,264 | 521,425 | Feb 25 |
| MCCOURT Thomas A | Chief Executive Officer | Feb 24 '26 | Sale | 3.66 | 103,526 | 378,905 | 1,489,002 | Feb 25 |
| John Minardo | Chief Legal Officer | Feb 24 '26 | Sale | 3.66 | 19,053 | 69,734 | 363,886 | Feb 25 |
| Martini Gregory S. | Chief Financial Officer | Feb 24 '26 | Sale | 3.66 | 11,457 | 41,933 | 160,601 | Feb 25 |
| Gaskins Tammi L | Chief Commercial Officer | Feb 24 '26 | Sale | 3.66 | 11,239 | 41,135 | 213,738 | Feb 25 |
| Silver Ronald | Principal Accounting Officer | Feb 24 '26 | Sale | 3.66 | 12,621 | 46,193 | 252,636 | Feb 25 |
| John Minardo | Chief Legal Officer | Feb 23 '26 | Sale | 3.81 | 17,439 | 66,443 | 382,939 | Feb 25 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | Feb 23 '26 | Sale | 3.81 | 15,570 | 59,322 | 538,437 | Feb 25 |
| Gaskins Tammi L | Chief Commercial Officer | Feb 23 '26 | Sale | 3.81 | 10,287 | 39,193 | 224,977 | Feb 25 |
| MCCOURT Thomas A | Chief Executive Officer | Feb 23 '26 | Sale | 3.81 | 94,757 | 361,024 | 1,592,528 | Feb 25 |
| Martini Gregory S. | Chief Financial Officer | Feb 23 '26 | Sale | 3.81 | 10,487 | 39,955 | 172,058 | Feb 25 |
| Silver Ronald | Principal Accounting Officer | Feb 23 '26 | Sale | 3.81 | 11,552 | 44,013 | 265,257 | Feb 25 |